Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients
Melodie Young, MSN, AGNP-C, FSDNP, DCNP; TJ Chao, MPAS, PA-C; Leigh Ann Pansch, MSN, FNP-BC, DCNP; and Douglas DiRuggiero, DMSc, MHS, PA-C, discuss how the transformative landscape of atopic dermatitis management now incorporates comprehensive severity assessment, personalized treatment goals, and strategic biologic selection based on mechanism of action, patient characteristics, and response patterns—with dupilumab, lebrikizumab, tralokinumab, and nemolizumab offering targeted approaches that demonstrate both rapid relief and long-term efficacy when optimally monitored and supported with appropriate adherence strategies.
